573 related articles for article (PubMed ID: 25515502)
1. Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Hahn AF; Vermeulen M; Venance SL; van Doorn PA
J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1331-6. PubMed ID: 25515502
[TBL] [Abstract][Full Text] [Related]
2. Treatment of immune-mediated, dysimmune neuropathies.
Finsterer J
Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
[TBL] [Abstract][Full Text] [Related]
3. Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; van Doorn PA; Bengrine T; van Rijs W; Baas F; Nagelkerke SQ; Kuijpers TW; Fokkink WR; Bunschoten C; Broers MC; Willemsen SP; Jacobs BC; Huizinga R
Eur J Neurol; 2021 May; 28(5):1677-1683. PubMed ID: 33460483
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
Eftimov F; Winer JB; Vermeulen M; de Haan R; van Schaik IN
Cochrane Database Syst Rev; 2009 Jan; (1):CD001797. PubMed ID: 19160200
[TBL] [Abstract][Full Text] [Related]
5. Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression.
Hung SKY; Hiew FL; Viswanathan S; Puvanarajah S
J Peripher Nerv Syst; 2018 Sep; 23(3):183-189. PubMed ID: 30027593
[TBL] [Abstract][Full Text] [Related]
6. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases.
Larue S; Bombelli F; Viala K; Neil J; Maisonobe T; Bouche P; Musset L; Fournier E; Léger JM
Eur J Neurol; 2011 Jun; 18(6):899-905. PubMed ID: 21199182
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations.
Dalakas MC; Latov N; Kuitwaard K
Expert Rev Neurother; 2022; 22(11-12):953-962. PubMed ID: 36645654
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.
Bus SRM; Broers MC; Lucke IM; Bunschoten C; van Lieverloo GGA; Adrichem ME; van Veen R; Wieske L; Lingsma HF; Goedee HS; van der Pol WL; van Schaik IN; Van Doorn PA; Jacobs BC; Eftimov F;
J Neurol; 2022 Feb; 269(2):945-955. PubMed ID: 34173873
[TBL] [Abstract][Full Text] [Related]
9. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
[TBL] [Abstract][Full Text] [Related]
10. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy.
Lucke IM; Wieske L; van der Kooi AJ; van Schaik IN; Eftimov F; Verhamme C
J Peripher Nerv Syst; 2019 Jun; 24(2):174-179. PubMed ID: 31090121
[TBL] [Abstract][Full Text] [Related]
12. Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Dyck PJ; Taylor BV; Davies JL; Mauermann ML; Litchy WJ; Klein CJ; Dyck PJ
Muscle Nerve; 2015 Oct; 52(4):488-97. PubMed ID: 25976871
[TBL] [Abstract][Full Text] [Related]
13. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.
Joint Task Force of the EFNS and the PNS
J Peripher Nerv Syst; 2005 Sep; 10(3):220-8. PubMed ID: 16221283
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
16. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
[TBL] [Abstract][Full Text] [Related]
17. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision.
Joint Task Force of the EFNS and the PNS
J Peripher Nerv Syst; 2010 Mar; 15(1):1-9. PubMed ID: 20433600
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
Lopate G; Pestronk A; Al-Lozi M
Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
[TBL] [Abstract][Full Text] [Related]
19. Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.
Bamrungsawad N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P; Dechanont S; Wu DB; Dejthevaporn C; Chaiyakunapruk N
Clin Drug Investig; 2016 Jul; 36(7):557-66. PubMed ID: 27113227
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
